by Naz Dana | Jul 23, 2018 | Business |
In the spring, we started introducing the Perlara Team – both new hires as well as not-so-new hires – on the blog. Around the same time, The New York Times launched a now-regular feature – Overlooked – recognizing women whose accomplishments...
by Julide Bilen | Jun 7, 2018 | PMM2-CDG |
An update on the development of PMM2 Drosophila models, and our work to design high throughput drug screen for PMM2 deficiency — Phosphomannomutase 2 deficiency (PMM2-CDG) is the most common type of congenital disorder of glycosylation resulting from a defect in...
by Ethan Perlstein | Jun 4, 2018 | Organic Intelligence, Science |
What is the role of OI in drug discovery? Organic Intelligence (OI) is the collective brainpower and high emotional quotient of scientists and rare disease advocates teaming up to use the PerlArk™ Platform of model organisms, lab automation and computation for a new...
by Joshua Mast | Apr 30, 2018 | Science |
My colleague, Tamy Portillo Rodriguez, and I attended the 59th Annual Drosophila Research Conference – a fantastic meeting of scientists exploring many different fields of biology using the fly – in Philadelphia earlier this month. The conference (in some...
by Ethan Perlstein | Apr 6, 2018 | MSD |
I’m excited to share the latest news! Today we announced our sixth PerlQuest partnership. Our PerlQuest partner is the Multiple Sulfatase Deficiency Action Foundation (MSDAF), a research-focused charity based in Ireland whose mission is to work towards a cure for...
